BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33825892)

  • 1. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
    Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
    Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
    J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
    Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
    Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
    Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
    J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
    Climans SA; Macdonald DR; Sutherland DE; Mason WP
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
    Lou E; Nelson AC; Kool M
    Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
    Kaye SB; Fehrenbacher L; Holloway R; Amit A; Karlan B; Slomovitz B; Sabbatini P; Fu L; Yauch RL; Chang I; Reddy JC
    Clin Cancer Res; 2012 Dec; 18(23):6509-18. PubMed ID: 23032746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups.
    Tonn S; Korshunov A; Obrecht D; Sill M; Spohn M; von Hoff K; Milde T; Pietsch T; Goschzik T; Bison B; Juhnke BO; Struve N; Sturm D; Sahm F; Bockmayr M; Friedrich C; von Bueren AO; Gerber NU; Benesch M; Jones DTW; Kool M; Wefers AK; Schüller U; Pfister SM; Rutkowski S; Mynarek M
    Neuro Oncol; 2023 Aug; 25(8):1518-1529. PubMed ID: 36715306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
    Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.
    Petrirena GJ; Masliah-Planchon J; Sala Q; Pourroy B; Frappaz D; Tabouret E; Graillon T; Gentet JC; Delattre O; Chinot O; Padovani L
    Oncotarget; 2018 Feb; 9(11):10175-10183. PubMed ID: 29515801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
    Maughan BL; Suzman DL; Luber B; Wang H; Glavaris S; Hughes R; Sullivan R; Harb R; Boudadi K; Paller C; Eisenberger M; Demarzo A; Ross A; Antonarakis ES
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1297-1304. PubMed ID: 27826729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
    Levy AS; Krailo M; Chi S; Villaluna D; Springer L; Williams-Hughes C; Fouladi M; Gajjar A
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29031. PubMed ID: 33844469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
    Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
    Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.